Syndax Pharmaceuticals, Inc. Restricted Cash and Cash Equivalents
Syndax Pharmaceuticals, Inc. (SNDX) had Restricted Cash and Cash Equivalents of $216.00 thousand as of 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2019-03-07
- 2018-12-31: Restricted Cash and Cash Equivalents $216.00K.
- 2018-09-30: Restricted Cash and Cash Equivalents $216.00K.
- 2018-06-30: Restricted Cash and Cash Equivalents $216.00K.
- 2018-03-31: Restricted Cash and Cash Equivalents $215.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2018-12-31 | $216.00K 10-K · filed 2019-03-07 |
| 2018-09-30 | $216.00K 10-Q · filed 2018-11-05 |
| 2018-06-30 | $216.00K 10-Q · filed 2018-08-08 |
| 2018-03-31 | $215.00K 10-Q · filed 2018-05-09 |
| 2017-12-31 | $221.00K 10-K · filed 2019-03-07 |
| 2016-12-31 | $266.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |